CervoMed Inc. (CRVO) AI Stock Analysis

CervoMed Inc. is a biotechnology firm specializing in the development and deployment of therapies aimed at addressing age-related neurologic disorders affecting the nervous system. At the forefront of its pipeline is neflamapimod, an orally administered small molecule designed to penetrate the brain. Neflamapimod is being developed for neurodegenerative conditions including dementia with Lewy bodies (DLB), Alzheimer's disease, frontotemporal dementia, and recovery from ischemic stroke. The company is also evaluating EIP200, a preclinical therapeutic candidate for central nervous system disorders. Founded in 2010 and based in Boston, Massachusetts, CervoMed operates with 15 employees.

Revenue rose from $7.1M in FY2023 to $9.7M in FY2024 before falling 58.9% to $4.0M in FY2025, resulting in a two-year revenue CAGR of -25.1%. Net losses widened from -$2.2M in FY2023 to -$16.3M in FY2024 and -$27.0M in FY2025 as research and development expenses reached $21.8M. Operating margin dropped from -109.3% in FY2023 to -706.2% in FY2025. Over the trailing twelve months, revenue totaled $331,295 with an operating margin of -9407.0% and an EPS of -$3.21. In the latest quarter ended June 30, 2026, quarterly revenue fell 99.6% year-over-year.

As of June 30, 2026, CervoMed held $24.9M in cash and short-term investments, representing most of its $26.0M in total assets, while shareholders' equity stood at $23.0M. The company maintained a current ratio of 8.57. Both operating cash flow and free cash flow were -$23.4M in FY2025, compared to -$16.5M in FY2024. Over a five-year period, the company's share count increased by 653.9%.

CervoMed has a market capitalization of $33.9M and an enterprise value of $13.3M. The stock trades at a price-to-sales multiple of 102.2x, compared to the median of 4.1x for its US-listed Healthcare peers. Its enterprise value-to-revenue ratio is 307.7x, and its price-to-book ratio is 1.7x. Over the past year, the stock declined 70.5%, and over five years it fell 93.8%, underperforming the S&P 500 (SPY), which gained 16.8% over one year and 83.0% over five years.

Wall Street analysts hold 6 Strong Buy ratings, 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings on CervoMed. The mean price target is $15.00, compared to the last close of $2.24 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate revenue of $133,330 and EPS of -$2.13. For the following fiscal year, 4 analysts estimate revenue of $833,330 and EPS of -$1.39. CervoMed beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 6, 2026.

This page is an AI-written research summary of CervoMed Inc. (CRVO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CRVO income statement, CRVO balance sheet, CRVO key metrics, CRVO analyst forecast, CRVO chart. See the CRVO stock overview for the latest quote and news.